Hydralazine/isosorbide dinitrate - Arbor Pharmaceuticals/NitroMed
Alternative Names: AR-06; BiDil; BiDil XR; Heart failure therapy - NitroMed; Hydralazine hydrochloride/isosorbide dinitrate; Isosorbide dinitrate/hydralazineLatest Information Update: 02 Oct 2021
At a glance
- Originator NitroMed
- Developer Arbor Pharmaceuticals; NitroMed
- Class Heart failure therapies; Organic nitrates; Peripheral vasodilators; Phthalazines; Small molecules
- Mechanism of Action Antioxidants; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Heart failure
Most Recent Events
- 02 Aug 2019 Phase-II development is ongoing in Heart failure in USA (PO, Controlled release)
- 06 Feb 2019 Chemical structure information added
- 30 Apr 2016 Arbor Pharmaceuticals completes a phase I/II trial in Heart failure in USA (NCT02522208)